Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia

Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia

“…Immunological recovery was markedly delayed during and after alemtuzumab therapy, with a prominent reduction in the T-cell compartment. 4 All three patients responded to alemtuzumab treatment with a42 g/dl rise in Hb concentration after a median of 8 weeks. Patient no.…”

Cryptococcosis in liver and kidney transplant recipients receiving anti‐thymocyte globulin or alemtuzumab

“…CD4+ T‐cell counts as low as 10 were observed. Studies on the immunologic effects of alemtuzumab have shown that the CD4+ T cells are the lymphocyte subpopulation most severely affected; counts may be lower than 25% of baseline at 9 months and lower than 50% of baseline at 12 months (1–6). Therefore, one can hypothesize that the use of ATG and alemtuzumab may impact the prevalence of cryptococcosis.…”

“…Rabbit ATG is a polyclonal antibody, and alemtuzumab is a humanized monoclonal antibody directed against CD52, a cell surface antigen expressed on B and T lymphocytes, monocytes and NK‐cells. The use of ATG and alemtuzumab as preconditioning may be associated with the development of partial tolerance, a lower incidence of rejection episodes, and a reduced dependence on maintenance immunosuppression and steroids (1–11).…”

“…Immunologic reconstitution studies performed in patients receiving ATG or alemtuzumab for the management of rheumatoid arthritis, B‐cell chronic lymphocytic leukemia, bone marrow transplantation, and solid organ transplantation have demonstrated that the most profound effects are on the CD4+ T lymphocyte subpopulation. The CD4+ T lymphocyte count remains less than 50% of baseline at 12 months (1–6).…”

Chronic Lymphocytic Leukemia With Eyelid Involvement Responding to Alemtuzumab

“…4 Treatment of LC in CLL patients until now has been the use of alkylating agent, nucleoside analogs such as fludarabine and cladribine, or interferon-␣ or local radiotherapy. 3 The use of low-dose alemtuzumab (10 mg three times a week as target dose) as previously reported [8][9][10][11] reduces the risk of toxicities and infection, especially if the T-helper lymphocyte count was constantly more than 200/mm 3 , and stringent antimicrobial prophylaxis and periodical viral tests were performed during alemtuzumab treatment. 7 The use of alemtuzumab in this setting of disease is never reported.…”